Archive for September, 2004Letter From the EditorTuesday, September 28th, 2004The NARCOMS MS Patient Registry, a project of the Consortium of Multiple Sclerosis Centers, is now entering its sixth year of operation. Over the last 6 years it has grown from a small pilot study executed in Connecticut to a nation-wide database that includes data on over 30,000 patients with multiple sclerosis (MS). As individuals [...] Epstein-Barr Virus in Pediatric MS: Results of a study of the Department of Pediatrics (Neurology), Al-Sabah Hospital, Shuwaikh, KuwaitSaturday, September 4th, 2004Context Dysphagia and Multiple Sclerosis: Results of a study conducted at Neurologisches Krankenhaus Munchen (NKM), Munich, GermanySaturday, September 4th, 2004Over 30% of people with multiple sclerosis (MS) suffer from swallowing symptoms, a higher rate than previously assumed. Neurogenic dysphagia (ND) may cause many different kinds of oropharyngeal sensorimotor dysfunctions in people with MS, and is associated with both the amount of disability and brainstem signs. About 15% of people with MS with mild disability [...] Disability as a Function of Disease DurationSaturday, September 4th, 2004Tuula Tyry, PhD, MAED, Program Manager, NARCOMS Project— Barrow Neurological Institute, St. Joseph’s Hospital, Phoenix, AZ A Summary of Rebif Clinical TrialsSaturday, September 4th, 2004Stacy Oswald, BS, MSQR Coorinator – Barrow Neurological Institute; and Timothy Vollmer, MD, Chief, Neuroimmunology Section – Division of Neurology and Director – Barrow MS and Related Diseases Clinic and Research Center, Phoenix, AZ Mitoxantrone: An Effective Drug for Secondary and Relapsing Progressive Forms of Multiple SclerosisSaturday, September 4th, 2004Craig H. Smith, MD, MS Hub Medical Group, Seattle, WA |
|